News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medivir AB (MVIRb.F) Has Initiated a Phase I Clinical Trial With Its Cathepsin K inhibitor MIV-711


5/29/2012 11:28:35 AM

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Medivir AB (OMX:MVIR), a research-based pharmaceutical company focused on infectious diseases, announced today that a phase I clinical trial has been initiated with its investigational drug, MIV-711, a cathepsin K inhibitor for the treatment of bone disorders characterized by excessive bone resorption such as osteoporosis, osteoarthritis and bone metastases.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES